The Need for New Strategies for Tumor Treatment

I think CKM5 is going to be used with a number of ADCs, having also an anti-mick retailer payload. We are now maybe in the times that we should think on targeted immunotherapy. The combination of Durbaloma plus an ATR inhibitor was actually better as compared to any other combination. I don't know exactly when we're going to see this, but Heather, you know, usually when we bring this up, people were like, what? But at least it's different and innovative.